Alpa Laboratories Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-07-17
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 25 Cr | 32 Cr | 27 Cr | 24 Cr | 21 Cr | 25 Cr | 26 Cr | 40 Cr | 19 Cr | 26 Cr | 29 Cr | 31 Cr |
| Operating expenses (approx.) | 27 Cr | 29 Cr | 25 Cr | 20 Cr | 21 Cr | 22 Cr | 25 Cr | 40 Cr | 19 Cr | 28 Cr | 28 Cr | 29 Cr |
| EBITDA | -1 Cr | 3 Cr | 2 Cr | 4 Cr | 0.53 Cr | 3 Cr | 0.74 Cr | 0.20 Cr | 0.42 Cr | -2 Cr | 2 Cr | 3 Cr |
| OPM % | -4.4% | 10.4% | 9.0% | 14.9% | 2.5% | 13.3% | 2.8% | 0.5% | 2.2% | -8.5% | 5.2% | 8.6% |
| Other income | 4 Cr | 3 Cr | 4 Cr | 4 Cr | 5 Cr | 7 Cr | 9 Cr | 2 Cr | 12 Cr | 3 Cr | 0.91 Cr | -0.16 Cr |
| Interest | 0.02 Cr | 0.02 Cr | 0.02 Cr | 0.29 Cr | 0.05 Cr | 0.05 Cr | 0.09 Cr | 0.02 Cr | 0.05 Cr | 0.03 Cr | 0.03 Cr | 0.15 Cr |
| Depreciation | 0.28 Cr | 0.49 Cr | 0.66 Cr | 0.52 Cr | 0.54 Cr | 0.53 Cr | 0.55 Cr | 0.58 Cr | 0.55 Cr | 0.67 Cr | 0.65 Cr | 0.22 Cr |
| Profit before tax | 3 Cr | 6 Cr | 5 Cr | 7 Cr | 5 Cr | 10 Cr | 9 Cr | 2 Cr | 12 Cr | 0.11 Cr | 2 Cr | 2 Cr |
| Tax % | 0.0% | 0.0% | 14.9% | 46.7% | 0.0% | 20.4% | 0.0% | 202.4% | 0.0% | 0.0% | -8.9% | 77.2% |
| Net profit | 3 Cr | 6 Cr | 5 Cr | 4 Cr | 5 Cr | 8 Cr | 9 Cr | -2 Cr | 12 Cr | 0.11 Cr | 2 Cr | 0.50 Cr |
| EPS (₹) | ₹1.44 | ₹2.75 | ₹2.17 | ₹1.71 | ₹2.42 | ₹3.66 | ₹4.23 | ₹-0.95 | ₹5.59 | ₹0.05 | ₹0.90 | ₹0.24 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 86 Cr | 98 Cr | 112 Cr | 92 Cr | 109 Cr | 112 Cr | 106 Cr | Sign in for TTM |
| Operating expenses (approx.) | 83 Cr | 90 Cr | 102 Cr | 85 Cr | 101 Cr | 108 Cr | 103 Cr | Sign in for TTM |
| EBITDA | 3 Cr | 8 Cr | 11 Cr | 8 Cr | 8 Cr | 5 Cr | 2 Cr | Sign in for TTM |
| OPM % | 3.9% | 7.9% | 9.5% | 8.2% | 7.5% | 4.2% | 2.3% | Sign in for TTM |
| Other income | 3 Cr | 4 Cr | 11 Cr | 10 Cr | 15 Cr | 23 Cr | 16 Cr | Sign in for TTM |
| Interest | 0.20 Cr | 0.08 Cr | 0.24 Cr | 0.22 Cr | 0.36 Cr | 0.23 Cr | 0.26 Cr | Sign in for TTM |
| Depreciation | 3 Cr | 1 Cr | 2 Cr | 1 Cr | 2 Cr | 2 Cr | 2 Cr | Sign in for TTM |
| Profit before tax | 3 Cr | 11 Cr | 20 Cr | 16 Cr | 21 Cr | 26 Cr | 16 Cr | Sign in for TTM |
| Tax % | 36.3% | 32.8% | 28.0% | 20.7% | 18.9% | 24.0% | 10.7% | Sign in for TTM |
| Net profit | 2 Cr | 7 Cr | 14 Cr | 13 Cr | 17 Cr | 20 Cr | 14 Cr | Sign in for TTM |
| EPS (₹) | ₹0.89 | ₹3.45 | ₹6.67 | ₹5.90 | ₹8.01 | ₹9.34 | ₹6.71 | Sign in for TTM |
| Dividend payout % | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity capital | 21 Cr | 21 Cr | 21 Cr | 21 Cr | 21 Cr | 21 Cr | 21 Cr |
| Reserves | 0.0000 Cr | 87 Cr | 101 Cr | 114 Cr | 131 Cr | 150 Cr | 165 Cr |
| Borrowings | — | — | — | 2 Cr | 5 Cr | — | 3 Cr |
| Other liabilities | — | — | — | 31 Cr | 25 Cr | 51 Cr | 53 Cr |
| Total liabilities | — | — | — | 167 Cr | 183 Cr | 223 Cr | 242 Cr |
| Fixed assets (net) | — | — | — | 7 Cr | 11 Cr | 21 Cr | 20 Cr |
| CWIP | — | — | — | 0.0000 Cr | 0.0000 Cr | 0.0000 Cr | 0.0000 Cr |
| Investments | — | — | — | 78 Cr | 98 Cr | 118 Cr | 142 Cr |
| Other assets | — | — | — | 153 Cr | 162 Cr | 192 Cr | 211 Cr |
| Total assets | — | — | — | 167 Cr | 183 Cr | 223 Cr | 242 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | 2 Cr | -5 Cr | 4 Cr | 7 Cr | 11 Cr |
| Cash from investing | — | — | -16 Cr | 1 Cr | -13 Cr | -1 Cr | -12 Cr |
| Cash from financing | — | — | 6 Cr | -3 Cr | 3 Cr | -5 Cr | 2 Cr |
| Net cash flow | — | — | -8 Cr | -7 Cr | -7 Cr | 0.48 Cr | 0.62 Cr |
| Free cash flow (OCF − Capex) | — | — | -0.21 Cr | -6 Cr | -3 Cr | -4 Cr | 7 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| ROCE % | 0.9% | 6.0% | 7.4% | 4.6% | 3.9% | 1.5% | 0.2% |
| ROE % | 0.0% | 0.0% | 0.0% | 0.0% | 11.0% | 0.0% | 7.6% |
| Debtor days | — | — | — | 184 | 139 | 152 | 140 |
| Inventory days | — | — | — | 84 | 79 | 91 | 77 |
| Days payable | — | — | — | 100 | 68 | 96 | 102 |
| Cash conversion cycle | — | — | — | 168 | 150 | 146 | 115 |
| Debt / equity | — | 0.00 | 0.00 | 0.02 | 0.03 | — | 0.01 |
| Current ratio | — | — | — | 4.98 | 5.69 | 4.10 | 4.01 |
| Net debt / EBITDA | 0.00 | 0.00 | 0.00 | -0.86 | 0.64 | -0.0056 | 0.78 |
Compare with peers
Loading peers…